Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-APP (mivelsiran) in cerebral amyloid angiopathy
2023-510137-29-01Phase 2Authorised
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Mar 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in cerebral amyloid angiopathy (CAA) comparing Mivelsiran with Placebo (2 arms). Primary endpoint: Annualized rate of new lobar cerebral microbleeds. Planned start Mar 2025; status: authorised.
02
Drugs
mivelsiran
03
Conditions
cerebral amyloid angiopathy (CAA)
Beyond the preview
Go deeper on 2023-510137-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510137-29-01.